TiumBio

At a glance

TiumBio filed 34 disclosures in the last 12 months, including 2 5% holder and 1 insider. The most recent key filing was on Oct 23: A major holder's stake rose from 30.91% to 31.17% (pledge).

Revenue for 2025 was ₩12.3B, up 80.9% on 2024. It made an operating loss of ₩16.1B. Debt was 161% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩7.4B and operating loss of ₩8.8B.

The 2025 annual report lists 67 employees with an average tenure of 3.2 years and average pay of ₩57.4M, #1095 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩170M each on average. It paid no cash dividend for 2025. 김훈택 and related parties held 30.84% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 31.17% on Oct 23.

From the 2025 annual report

Staff: 67 (36 men, 31 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩3.9B. Directors and auditors: 6, paid ₩850M in total.

No cash dividend was paid for 2025.

Largest shareholder

김훈택 holds 28.95%; with 8 related parties the group holds 30.84% of common shares at year end (from 29.55% at the start of the year).

Auditor: 태성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports